Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE ‐013-Reference-Cited by-同舟云学术

Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE ‐013

Published:2019-04 Issue: Volume: Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Ribrag Vincent¹^ORCID,Avigan David E.²,Green Damian J.³,Wise‐Draper Trisha⁴,Posada Juan G.⁵,Vij Ravi⁶,Zhu Ying⁷,Farooqui Mohammed Z. H.⁷,Marinello Patricia⁷,Siegel David S.⁸

Affiliation:

1. Institut Gustave Roussy VillejuifFrance

2. Beth Israel Deaconess Medical Center Harvard Medical School Boston MA

3. University of Washington Fred Hutchinson Cancer Research Center Seattle WA

4. University of Cincinnati Cancer Institute Cincinnati OH

5. Central Texas Veterans Affairs Health Care System Temple TX

6. Center for Advanced Medicine Washington University School of Medicine St. Louis MO

7. Merck & Co., Inc. Kenilworth NJ

8. Hackensack University Medical Center Hackensack NJ

Funder

Merck Sharp and Dohme

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15888

Reference7 articles.

1. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma

2. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

3. International uniform response criteria for multiple myeloma

4. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017

5. New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Momordin Ic that selectively reduces PD-L1 expression in multiple myeloma cells by recruiting SYVN1;Food Bioscience;2024-10

2. Mechanisms of resistance to daratumumab in patients with multiple myeloma;Basic & Clinical Pharmacology & Toxicology;2024-08-26

3. The Evolving Role of Checkpoint Inhibitors in Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-08

4. Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies;Cancer Communications;2024-07-28

5. Advancements in microenvironment-based therapies: transforming the landscape of multiple myeloma treatment;Frontiers in Oncology;2024-07-17